Organization
UCB Pharma, Raleigh, United States
2 abstracts
Abstract
5-YEAR RESULTS FROM THE RAPID 1 TRIAL AND OPEN-LABEL EXTENSION: LONG-TERM SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS Org: UCB Pharma, Raleigh, United States,
Abstract
A RANDOMIZED DOUBLE-BLIND TREATMENT STRATEGY STUDY EVALUATING CONTINUATION OR REDUCED-FREQUENCY DOSING OF CERTOLIZUMAB PEGOL VERSUS WITHDRAWAL TO MAINTAIN LOW DISEASE ACTIVITY IN EARLY RA PATIENTS (C-EARLY PERIOD 2) Org: Weill Cornell College, New York, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, UCB Pharma, Raleigh, United States, UCB Pharma, Brussels, Belgium,